Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the sale of certain assets related to its hemofiltration product line to Baxter International Inc. (NYSE: BAX), consistent with the previously announced terms of the agreement.
"The completion of this transaction allows us to better focus resources on our strategic initiatives while benefitting Edwards' hemofiltration employees, products and customers," said Carlyn D. Solomon, Edwards' corporate vice president, Critical Care and Vascular.
Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A